Rezolute Inc. (RZLT)

[Whalatane]

RZLT.

Cash, cash equivalents and investments in marketable securities were $81.6 million as of March 31, 2024,

Maybe market is pricing in a capital raise .
What are the Co's options re developing the DME indication
1) sell / partner with a BP
2) Raise $ and try and do a pivotal P 3 DME trial themselves ...probably international , 1,000 patients , min 12 mth set up , 12 mth data needed plus another 3 mths till readout = $50-$100m ??
3) Let the program die if BP is not interested

Kiwi